Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas W Fischer

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Oncotarget|July 9, 2016
Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor networkNardin Samuel, Gavin Wilson, Badr Id Said, et al.
Iscience|December 5, 2024
Clustering of <i>TP53</i> variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndromeEmilie Montellier, Nathanaël Lemonnier, Judith Penkert, et al.
Cancers|July 30, 2020
<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard ChemotherapyFrancesco Graziano, Nicholas W Fischer, Irene Bagaloni, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Oncotarget|July 9, 2016
Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor networkNardin Samuel, Gavin Wilson, Badr Id Said, et al.
Iscience|December 5, 2024
Clustering of <i>TP53</i> variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndromeEmilie Montellier, Nathanaël Lemonnier, Judith Penkert, et al.
Cancers|July 30, 2020
<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard ChemotherapyFrancesco Graziano, Nicholas W Fischer, Irene Bagaloni, et al.
Pageof 2